AKI: Biomarker Guided Therapies
AKI: Biomarker Guided Therapies
批准号:
8548119
负责人:
STUART L GOLDSTEIN
金额:
$10.11万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AcuteAcute Renal Failure with Renal Papillary NecrosisAnimalsBedside TestingsBiological MarkersCaringChildChild MortalityChildhoodClinicalCreatinineCreatinine clearance measurementCritically ill childrenDevelopmentDiagnosisDialysis procedureFenoldopamGelatinase AGenomicsHourInjuryKidneyKidney DiseasesLiquid substanceNephrologyOperative Surgical ProceduresOutcomeOutputPatientsPlasmaProteomicsPublic HealthRecoveryResearch PersonnelRiskSerumTechnologyUrinebaseimprovedmultidisciplinarynovelpreventtranslational studyurinary
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Acute Kidney Injury (AKI) is a common clinical problem defined by an abrupt (¿ 48 hour) increase in serum
creatinine (SCr) resulting from an injury or insult causing a functional or structural change in the kidney.
Despite significant advancements in the care of the critically ill child, mortality rates in children who develop
AKI have not improved. Using genomic and proteomic technologies, we identified neutrophil gelatinase-associated
lipocalin (NGAL) as a biomarker that is produced in high levels in the kidney very early after
kidney injury. We have developed three aims for these complementary studies: NGAL directed therapy to
prevent AKI, NGAL directed therapy to optimize support for patients who develop AKI and biomarker/
proteomic profiling to predict or detect CKD development early. Accordingly the specific aims of this proposal
are: Aim 1. Prevent AKI - this aim will determine if the administration of fenoldopam to children at risk for
AKI, based upon plasma NGAL point of care testing, will prevent the occurrence of AKI following CPB. AKI
will be determined based on the modified pediatric RIFLE (pRIFLE) criteria. Using pRIFLE, AKI will be
defined as an estimated creatinine clearance decrease by <:: 25% from preoperative baseline level or urine
output < 0.5 ml/kg/hr for 6 hours within 48h of surgery. Aim 2. Prevent acute complications of AKI - this aim
will determine if persistently elevated NGAL can predict which critically ill children will ultimately develop
significant (>10%) positive ICU fluid accumulation for more than 24 hours and thereby optimize dialysis
initiation. Aim 3: Predict long term consequences of AKI - this aim will assess urinary proteomic profiles for
discovery of novel biomarkers to predict the AKI recovery and/or transition of AKI to CKD. The
multidisciplinary team of investigators, including pediatric nephrologists, intensivists, cardiologists, and
biostatisticians will extensively employ the Proteomics Core (Core B) and the Biomarker Core (Core C) for
the successful completion of this project.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Reduction of Nephrotoxic Medication-Associated Acute Kidney Injury in Children
-
批准号:9042945
-
项目类别:
-
资助金额:$49.83万
-
财政年份:2015
-
负责人:STUART L GOLDSTEIN
-
依托单位:
Reduction of Nephrotoxic Medication-Associated Acute Kidney Injury in Children
-
批准号:8853551
-
项目类别:
-
资助金额:$49.86万
-
财政年份:2015
-
负责人:STUART L GOLDSTEIN
-
依托单位:
Reduction of Nephrotoxic Medication-Associated Acute Kidney Injury in Children
-
批准号:9226000
-
项目类别:
-
资助金额:$49.76万
-
财政年份:2015
-
负责人:STUART L GOLDSTEIN
-
依托单位:
AKI: Biomarker Guided Therapies
-
批准号:8397976
-
项目类别:
-
资助金额:$12.1万
-
财政年份:--
-
负责人:STUART L GOLDSTEIN
-
依托单位:
AKI: Biomarker Guided Therapies
-
批准号:8731223
-
项目类别:
-
资助金额:$10.33万
-
财政年份:--
-
负责人:STUART L GOLDSTEIN
-
依托单位: